ABVC BIOPHARMA INC (ABVC)
US00091F3047 - Common Stock
ABVC BIOPHARMA INC
NASDAQ:ABVC (4/25/2024, 10:11:20 AM)
1.4314
-0.05 (-3.28%)
Company Profile
ABVC Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fremont, California and currently employs 19 full-time employees. The company went IPO on 2004-11-09. ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of drugs and medical devices derived from plants. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. The company has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, ABV-1703 and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1702 is used to treat myelodysplastic syndrome (MDS). ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. Its ABV-1519 is used for the treatment of non-small cell lung cancer.
Company Info
ABVC BIOPHARMA INC
44370 Old Warm Springs Blvd
Fremont CALIFORNIA
P: 15106680881
CEO: Howard Doong
Employees: 19
Website: https://abvcpharma.com/
ABVC News
2 days ago - ChartmillWhich stocks are moving after the closing bell on Tuesday?Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) (
7 days ago - NewMediaWireAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
7 days ago - TheNewswire.comAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareFREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
8 days ago - NewMediaWireABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
15 days ago - TheNewswire.comABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MFREMONT, CA - (NewMediaWire) - April 10, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Shares within 30 days of execution of the Definitive Agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and Royalties of 5% of net sales, up to $50,000,000, after the launch of the Licensed Products.
ABVC Twits
Here you can normally see the latest stock twits on ABVC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
